ANI Pharmaceuticals reported a robust quarter with record-setting financial performance, driven by strong growth in both Rare Disease and Generics segments. While the company raised its 2025 guidance significantly, it continues to face market access challenges in the retina segment and is dealing with litigation-related setbacks. The overall sentiment is positive due to the company's strong financial performance and growth outlook.

Company Guidance -

Q3 2025

During ANI Pharmaceuticals' Q2 2025 earnings call, the company announced a raised guidance for the fiscal year 2025, highlighting a strong quarter with record-setting highs in net revenue, adjusted non-GAAP EBITDA, and adjusted non-GAAP EPS. The company now expects total net revenues for 2025 to be between $818 million and $843 million, reflecting a 33% to 37% growth over 2024. Adjusted non-GAAP EBITDA is projected to range from $213 million to $223 million, marking a 37% to 43% increase over the previous year, while adjusted non-GAAP EPS is anticipated to be between $6.98 and $7.35. This optimistic outlook is primarily driven by the robust performance of ANI's Rare Disease segment, particularly the Cortrophin Gel, which is now expected to generate revenues of $322 million to $329 million, up from prior guidance of $265 million to $274 million. The company attributes this growth to increased demand across various therapeutic areas, successful commercial strategies, and the introduction of a new prefilled syringe presentation that has been well-received by patients and physicians.

Record-Setting Quarter

ANI Pharmaceuticals achieved all-time highs in net revenue, adjusted non-GAAP EBITDA, and adjusted non-GAAP EPS, with significant growth across Rare Disease and Generics business units.

Raised 2025 Guidance

The company increased its 2025 guidance, expecting revenues to reach $818 million to $843 million, representing a growth of 33% to 37% over 2024. Adjusted non-GAAP EBITDA guidance was raised to $213 million to $223 million, reflecting a growth of 37% to 43%.

Cortrophin Gel Performance

Cortrophin Gel revenues surged to $81.6 million, up 66% year-over-year and 54% from the first quarter of 2025. New patient starts and new cases initiated reached record highs.

Generics Business Growth

The Generics business reported revenues of $90.3 million, an increase of 22% over the prior year period, driven by new product launches and strong operational execution.

Strong Cash Flow and Balance Sheet

ANI ended the second quarter with $217.8 million in unrestricted cash, up from $149.8 million at the end of the first quarter. Cash flow from operations was $110.8 million in the first half of the year.

ANI Pharmaceuticals (ANIP) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ANIP Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	1.66 / -	1.34	―	―	―
Aug 08, 2025	2025 (Q2)	1.41 / 1.80	1.02	76.47% (+0.78)	―
May 09, 2025	2025 (Q1)	1.38 / 1.70	1.21	40.50% (+0.49)	―
Feb 28, 2025	2024 (Q4)	1.44 / 1.63	1	63.00% (+0.63)	―
Nov 08, 2024	2024 (Q3)	1.09 / 1.34	1.27	5.51% (+0.07)	―
Aug 06, 2024	2024 (Q2)	0.95 / 1.02	1.28	-20.31% (-0.26)	―
May 10, 2024	2024 (Q1)	1.00 / 1.21	1.17	3.42% (+0.04)	―
Feb 29, 2024	2023 (Q4)	0.85 / 1.00	0.76	31.58% (+0.24)	―
Nov 08, 2023	2023 (Q3)	0.84 / 1.27	0.64	98.44% (+0.63)	―
Aug 09, 2023	2023 (Q2)	0.67 / 1.28	0.13	884.62% (+1.15)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ANIP Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 08, 2025	$69.01	$81.48	+18.07%
May 09, 2025	$71.53	$66.30	-7.31%
Feb 28, 2025	$54.58	$61.89	+13.39%
Nov 08, 2024	$58.38	$61.44	+5.24%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does ANI Pharmaceuticals Inc (ANIP) report earnings?

ANI Pharmaceuticals Inc (ANIP) is schdueled to report earning on Nov 05, 2025, Before Open (Confirmed).

What is ANI Pharmaceuticals Inc (ANIP) earnings time?

ANI Pharmaceuticals Inc (ANIP) earnings time is at Nov 05, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ANIP EPS forecast?

ANIP EPS forecast for the fiscal quarter 2025 (Q3) is 1.66.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing